Chemomab: Publications ‘reinforce’ potential of I CCL24 antibody for PSC

Chemomab Therapeutic announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis PSC. The new study reinforces the extensive evidence showing the potential of Chemomab’s CCL24-neutralizing antibody, CM-101, to interrupt the biological processes driving PSC disease progression and severity. The study, “Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis”1 has been published in the current online version of the peer-reviewed International Journal of Molecular Science.T …Notably, the analysis showed that enrichment for PSC-related biological pathways was associated with high levels of CCL24 and that patients with cirrhosis had higher levels of CCL24, providing further evidence for the role of CCL24 in disease progression and severity. The authors also noted that the biomarkers identified in this study have significant translational importance, offering potential advancements in the monitoring of disease progression in clinical settings. “These proteomic analyses add to the large body of data showing that CCL24 is a major driver of PSC disease progression and severity….”We look forward to our CM-101 PSC Phase 2 topline data readout in the coming weeks, which has the potential to provide the first significant clinical proof-of-concept of CM-101’s therapeutic activity in this lethal disease with no FDA approved therapies.”